Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab vs Interferon Beta-1a in Relapsing MS (OPERA II)
NCT01412333Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2011
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Started Sep 2011; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01412333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01412333.